Adimmune (TPE:4142) Other Current Liabilities: NT$51 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4142 Adimmune Corp TPE:4142
55 GF Score
Price NT$17.45
GF Value NT$25.71
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Adimmune Other Current Liabilities?

Adimmune TPE:4142 +3.56% 55 Other Current Liabilities is NT$51 Mil as of Dec. 2025. GuruFocus rates TPE:4142 with a GF Score™ of 55/100 and a GF Value™ of NT$25.71 (Possible Value Trap). The stock has 6 warning signs investors should review.

Adimmune's other current liabilities for the quarter that ended in Dec. 2025 was NT$51 Mil.

Adimmune's quarterly other current liabilities declined from Jun. 2025 (NT$101 Mil) to Sep. 2025 (NT$19 Mil) but then increased from Sep. 2025 (NT$19 Mil) to Dec. 2025 (NT$51 Mil).

Adimmune's annual other current liabilities declined from Dec. 2023 (NT$266 Mil) to Dec. 2024 (NT$36 Mil) but then increased from Dec. 2024 (NT$36 Mil) to Dec. 2025 (NT$51 Mil).

Adimmune Other Current Liabilities Related Terms

Adimmune Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Adimmune's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adimmune Other Current Liabilities Chart

Adimmune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.50 27.42 265.93 36.01 51.09

Adimmune Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.01 96.33 101.34 18.82 51.09
TPE:4142
55GF Score
Adimmune Corp TPE:4142
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adimmune Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of NT$51 Mil mean?
Adimmune (TPE:4142) has a Other Current Liabilities of NT$51 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Adimmune.
Is Adimmune's Other Current Liabilities too high?
Adimmune's current Other Current Liabilities is NT$51 Mil. Overall, Adimmune has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Adimmune's Other Current Liabilities compare to VRTX and REGN?
Adimmune's Other Current Liabilities of NT$51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Adimmune. Adimmune's current Other Current Liabilities is NT$51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adimmune stock overvalued right now?
Based on GuruFocus' analysis, Adimmune (TPE:4142) is currently considered Possible Value Trap. The stock's GF Value™ is NT$25.71, compared to a current price of NT$17.45 — trading 32.1% below its estimated fair value. The current Other Current Liabilities is NT$51 Mil. Adimmune's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Adimmune (TPE:4142), the current Other Current Liabilities is NT$51 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adimmune (TPE:4142) Overvalued in 2026?

Based on GuruFocus' analysis, Adimmune stock appears to be undervalued. The current stock price of NT$17.45 is trading 32.1% below its estimated GF Value™ of NT$25.71. GuruFocus considers Adimmune to be Possible Value Trap.

Key valuation signals for TPE:4142:

  • Other Current Liabilities: NT$51 Mil
  • GF Value™: NT$25.71 vs. price of NT$17.45 (32.1% below fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the TPE:4142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adimmune Business Description

Address Tanxing Road, No. 3, Section 1, Tanzi District, Taichung City, TWN, 427003
Adimmune Corp is engaged in the research and development, processing, manufacturing, and trading of serum, vaccines, testing reagents, biologicals, and other bacterial fluids, as well as western medicines, animal medicines, chemicals, and feed additives. Its segments are separated by business as Adimmune Corporation, which generates maximum revenue and is engaged in the manufacturing of influenza vaccines with EU GMP and US FDA certificates in Taiwan. Its products include Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, and others, and Enimmune Corporation. The Group's revenue is mainly from the manufacturing and trading of vaccines, modern medicine products and testing reagents, as well as entrusted packing of vaccines.
55GF Score

Get the complete analysis for TPE:4142

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$17.45
Price
NT$25.71
GF Value